SLR HC BDC 10-Q 7 Nov 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page	9 Months Ended
	Sep. 30, 2023 shares
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	SLR HC BDC LLC
Entity Central Index Key	0001832148
Entity File Number	000-56247
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Transition Report	false
Document Quarterly Report	true
Entity Tax Identification Number	85-1801692
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	500 Park Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	212
Local Phone Number	993-1670
Entity Common Stock, Shares Outstanding	1,069,642

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands	Sep. 30, 2023		Dec. 31, 2022
Investments at fair value:
Cash	$ 2,286		$ 3,986
Cash equivalents (cost: $11,913 and $29,828, respectively)	11,913		29,828
Interest receivable	432		271
Prepaid expenses	35		15
Receivable for investments sold	11		0
Total assets	69,005		77,997
Liabilities
Payable for cash equivalents purchased	11,913		29,828
Management fee payable (see note 3)	367		325
Administration fee payable (see note 3)	11		8
Interest payable (see note 5)	834		493
Other liabilities and accrued expenses	227		193
Total liabilities	45,940		58,649
Commitments and contingencies (see note 6)
Unitholders' Capital
Common Unitholders' capital (1,069,642 and 888,565 units, respectively, issued and outstanding)	23,461		19,461
Accumulated distributable net loss	(396)		(113)
Total unitholders' capital	23,065	[1],[2]	19,348
Total liabilities and unitholders' capital	$ 69,005		$ 77,997
Net asset value per unit	$ 21.56		$ 21.77	[3]
Non Controlled Non Affiliated Investments [Member]
Investments at fair value:
Non-controlled/non-affiliated investments (cost: $53,845 and $43,602, respectively)	$ 54,328		$ 43,897
Revolving credit facility due February Two Thousand And Twenty Seven the SPV Facility [Member]
Liabilities
Long-Term Line of Credit	18,844		14,051
Revolving credit facility due March Two Thousand And Twenty Four the Subscription Facility [Member]
Liabilities
Long-Term Line of Credit	$ 13,744		$ 13,751
[1]Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per Unit. Total return does not include a sales load.[2]Not annualized for periods less than one year.[3]Calculated using the average Units outstanding method. Weighted average Units outstanding for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were 1,015,916 and 682,427, respectively.

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Investment owned, at Cost	$ 65,758	$ 73,430
Cash equivalents, at Cost	$ 11,913	$ 29,828
Common unit, Issued	1,069,642	1,069,642
Common unit, Outstanding	888,565	888,565
Revolving credit facility due February Two Thousand And Twenty Seven the SPV Facility [Member]
Long term debt, Gross	$ 19,610	$ 14,675
Debt issuance costs, Line of credit arrangements, Gross	766	624
Revolving credit facility due March Two Thousand And Twenty Four the Subscription Facility [Member]
Long term debt, Gross	13,800	13,800
Debt issuance costs, Line of credit arrangements, Gross	56	49
Non Controlled Non Affiliated Investments [Member]
Investment owned, at Cost	$ 53,845	$ 43,602

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investment Income:
Total investment income	$ 1,719	$ 893	$ 4,821	$ 2,388
Expenses:
Management fees (see note 3)	143	118	408	291
Administration fees (see note 3)	10	7	30	19
Interest and other credit facility expenses (see note 5)	1,106	581	2,854	1,196
Other general and administrative expenses	177	159	561	450
Total expenses	1,436	865	3,853	1,956
Net investment income	283	28	968	432
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized loss on non-controlled/non-affiliated investments and cash equivalents	(2)	(5)	(17)	(11)
Net change in unrealized gain on non-controlled/non-affiliated investments and cash equivalents	129	142	188	187
Net realized and unrealized gain on non-controlled/non-affiliated investments and cash equivalents	127	137	171	176
Net Increase in Unitholders' Capital Resulting From Operations	$ 410	$ 165	$ 1,139	$ 608
Net Income Per Unit	$ 0.38	$ 0.24	$ 1.12	$ 0.89
Investments and cash equivalents [Member]
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized loss on non-controlled/non-affiliated investments and cash equivalents			$ (17)	$ (11)
Net change in unrealized gain on non-controlled/non-affiliated investments and cash equivalents	$ 129	$ 142	188	187
Non Controlled Non Affiliated Investments [Member]
Investment Income:
Interest income from non-controlled/non-affiliated investments	1,702	886	4,795	2,372
Other income from non-controlled/non-affiliated investments	17	7	26	16
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized loss on non-controlled/non-affiliated investments and cash equivalents	$ (2)	$ (5)	$ (17)	$ (11)

Consolidated Statements of Chan

Consolidated Statements of Changes in Unitholders' Capital - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Increase (decrease) in unitholders' capital resulting from operations:
Net investment income	$ 283	$ 28	$ 968	$ 432
Net realized loss	(2)	(5)	(17)	(11)
Net change in unrealized gain	129	142	188	187
Net Increase in Unitholders' Capital Resulting From Operations	410	165	1,139	608
Distributions to unitholders:
From distributable earnings	(540)	(349)	(1,422)	(349)
Increase in unitholders' capital resulting from capital activity:
Contributions	0	0	4,000	0
Net increase in unitholders' capital resulting from capital activity	0	0	4,000	0
Total increase (decrease) in unitholders' capital	(130)	(184)	3,717	259
Unitholders' capital, beginning of period	23,195	15,055	19,348	14,612
Unitholders' capital, end of period	$ 23,065	$ 14,871	$ 23,065	$ 14,871
Capital unit activity (see note 7):
Units issued	0	0	181,077	0
Net increase from capital unit activity	0	0	181,077	0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities:
Net increase in unitholders' capital resulting from operations	$ 1,139	$ 608
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash used in operating activities:
Net realized loss on investments and cash equivalents	17	11
Deferred financing costs	247	250
(Increase) decrease in operating assets:
Purchase of investments	(15,118)	(17,233)
Net accretion of discount on investments	(351)	(156)
Proceeds from disposition of investments	5,507	4,582
Capitalization of payment-in-kind income	(298)	(71)
Interest receivable	(161)	(4)
Prepaid expenses	(20)	(25)
Receivable for investments sold	(11)	(12)
Increase (decrease) in operating liabilities:
Payable for cash equivalents purchased	(17,915)	9,881
Management fee payable	42	207
Administration fee payable	3	3
Interest payable	341	343
Other liabilities and accrued expenses	34	11
Net Cash Used in Operating Activities	(26,732)	(1,792)
Cash Flows from Financing Activities:
Contributions from unitholders	4,000	0
Cash distributions paid	(1,422)	(349)
Proceeds from borrowings	16,289	26,251
Repayments of borrowings	(11,750)	(13,500)
Net Cash Provided by Financing Activities	7,117	12,402
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(19,615)	10,610
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	33,814	20,467
CASH AND CASH EQUIVALENTS AT END OF PERIOD	14,199	31,077
Supplemental disclosure of cash flow information:
Cash paid for interest	2,513	853
Investments and cash equivalents [Member]
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash used in operating activities:
Net realized loss on investments and cash equivalents	17	11
Investments [Member]
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash used in operating activities:
Net change in unrealized gain on investments	$ (188)	$ (187)

Consolidated Schedule of Invest

Consolidated Schedule of Investments - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2023		Dec. 31, 2022
Schedule of Investments [Line Items]
Cost		$ 65,758		$ 73,430
Investments Cash and Cash Equivalents at Fair Value.		66,241		73,725
Liabilities in Excess of Other Assets		(43,176)		(54,377)
Net Assets		$ 23,065		$ 19,348
Percentage of Total Investments		100%		100%
Health Care Providers Services [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		48%		34.90%
Health Care Equipment Supplies [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		17%		19.30%
Pharmaceuticals [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		13.40%		16.50%
Biotechnology [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		12.20%		16.80%
Life Sciences Tools Services [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		7.40%		9.20%
Health Care Technology [Member]
Schedule of Investments [Line Items]
Percentage of Total Investments		2%		3.30%
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans
Schedule of Investments [Line Items]
Cost		$ 53,808		$ 43,577
Fair Value		$ 54,316		$ 43,886
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Apeel Technology Inc | Biotechnology | S+ 625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	8.75%
Acquisition Date	[2]	Jun. 29, 2022
Maturity Date	[2]	Jun. 01, 2027
Par Amount	[2]	$ 317
Cost	[2]	317
Fair Value	[2]	$ 353
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			625%
Floor	[2]			1%
Interest Rate	[2],[5]			8.75%
Acquisition Date	[2]			Jun. 29, 2022
Maturity Date	[2]			Jun. 01, 2027
Par Amount	[2]			$ 317
Cost	[2]			315
Fair Value	[2]			$ 317
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2],[6]	745%
Floor	[2],[6]	0.10%
Interest Rate	[2],[3],[6]	12.88%
Acquisition Date	[2],[6]	Dec. 22, 2021
Maturity Date	[2],[6]	Jan. 01, 2027
Par Amount	[2],[6]	$ 6,288
Cost	[2],[6]	6,397
Fair Value	[2],[6]	$ 6,398
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc. | Health Care Pharmaceuticals | L+745 | 0.10% | 11.62% | 12/22/2021 | 1/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4],[7]			745%
Floor	[2],[7]			0.10%
Interest Rate	[2],[5],[7]			11.62%
Acquisition Date	[2],[7]			Dec. 22, 2021
Maturity Date	[2],[7]			Jan. 01, 2027
Par Amount	[2],[7]			$ 6,288
Cost	[2],[7]			6,322
Fair Value	[2],[7]			$ 6,367
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ardelyx Inc | Pharmaceuticals | S+ 795 |1.00% | 13.30% | 2/23/2022 | 3/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2],[6]	795%
Floor	[2],[6]	1%
Interest Rate	[2],[3],[6]	13.30%
Acquisition Date	[2],[6]	Feb. 23, 2022
Maturity Date	[2],[6]	Mar. 01, 2027
Par Amount	[2],[6]	$ 851
Cost	[2],[6]	861
Fair Value	[2],[6]	$ 878
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4],[7]			795%
Floor	[2],[7]			0.10%
Interest Rate	[2],[5],[7]			12.12%
Acquisition Date	[2],[7]			Feb. 23, 2022
Maturity Date	[2],[7]			Mar. 01, 2027
Par Amount	[2],[7]			$ 851
Cost	[2],[7]			854
Fair Value	[2],[7]			$ 853
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BayMark Health Services Inc | Health Care Providers & Services | S+ 500 |1.00% | 10.65%| 6/29/2021 | 6/11/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	500%
Floor	[2]	1%
Interest Rate	[2],[3]	10.65%
Acquisition Date	[2]	Jun. 29, 2021
Maturity Date	[2]	Jun. 11, 2027
Par Amount	[2]	$ 4,037
Cost	[2]	4,009
Fair Value	[2]	$ 4,037
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			500%
Floor	[2]			1%
Interest Rate	[2],[5]			9.73%
Acquisition Date	[2]			Jun. 29, 2021
Maturity Date	[2]			Jun. 11, 2027
Par Amount	[2]			$ 4,068
Cost	[2]			4,034
Fair Value	[2]			$ 4,068
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc | Biotechnology | 9.00.%| 11/17/2021 | 11/17/2026
Schedule of Investments [Line Items]
Interest Rate	[2],[3],[6],[8]	9%
Acquisition Date	[2],[6]	Nov. 17, 2021
Maturity Date	[2],[6]	Nov. 17, 2026
Par Amount	[2],[6]	$ 3,767
Cost	[2],[6]	3,759
Fair Value	[2],[6]	$ 3,777
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026
Schedule of Investments [Line Items]
Interest Rate	[2],[5],[7],[8]			9%
Acquisition Date	[2],[7]			Nov. 17, 2021
Maturity Date	[2],[7]			Nov. 17, 2026
Par Amount	[2],[7]			$ 3,683
Cost	[2],[7]			3,656
Fair Value	[2],[7]			$ 3,683
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.59% | 5/22/2023 | 5/22/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.59%
Acquisition Date	[2]	May 22, 2023
Maturity Date	[2]	May 22, 2029
Par Amount	[2]	$ 1,400
Cost	[2]	1,359
Fair Value	[2]	$ 1,358
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Cerapedics Inc | Biotechnology | S+ 620 | 2.75% | 11.53%| 12/27/2022 | 1/1/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	620%
Floor	[2]	2.75%
Interest Rate	[2],[3]	11.53%
Acquisition Date	[2]	Dec. 27, 2022
Maturity Date	[2]	Jan. 01, 2028
Par Amount	[2]	$ 2,494
Cost	[2]	2,500
Fair Value	[2]	$ 2,501
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 10.52% | 12/27/2022 | 1/1/2028
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			620%
Floor	[2]			2.75%
Interest Rate	[2],[5]			10.52%
Acquisition Date	[2]			Dec. 27, 2022
Maturity Date	[2]			Jan. 01, 2028
Par Amount	[2]			$ 2,494
Cost	[2]			2,488
Fair Value	[2]			$ 2,488
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.63%
Acquisition Date	[2]	Jan. 04, 2023
Maturity Date	[2]	Jan. 03, 2029
Par Amount	[2]	$ 2,650
Cost	[2]	2,578
Fair Value	[2]	$ 2,650
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Glooko Inc | Health Care Technology | S+790 | 0.10% | 13.33% | 9/30/2021 | 10/1/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	790%
Floor	[2]	0.10%
Interest Rate	[2],[3]	13.33%
Acquisition Date	[2]	Sep. 30, 2021
Maturity Date	[2]	Oct. 01, 2026
Par Amount	[2]	$ 1,089
Cost	[2]	1,098
Fair Value	[2]	$ 1,111
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			790%
Floor	[2]			0.10%
Interest Rate	[2],[5]			12.07%
Acquisition Date	[2]			Sep. 30, 2021
Maturity Date	[2]			Oct. 01, 2026
Par Amount	[2]			$ 1,452
Cost	[2]			1,456
Fair Value	[2]			$ 1,455
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			625%
Floor	[2]			1%
Interest Rate	[2],[5]			10.39%
Acquisition Date	[2]			Dec. 22, 2021
Maturity Date	[2]			Feb. 25, 2026
Par Amount	[2]			$ 2,697
Cost	[2]			2,659
Fair Value	[2]			$ 2,724
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	675%
Floor	[2]	1%
Interest Rate	[2],[3]	12.48%
Acquisition Date	[2]	Mar. 01, 2023
Maturity Date	[2]	Mar. 01, 2029
Par Amount	[2]	$ 1,766
Cost	[2]	1,716
Fair Value	[2]	$ 1,766
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Meditrina Inc | Health Care Equipment & Supplies | S+ 550 |3.45% | 10.83%| 12/20/2022 | 12/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	3.45%
Interest Rate	[2],[3]	10.83%
Acquisition Date	[2]	Dec. 20, 2022
Maturity Date	[2]	Dec. 01, 2027
Par Amount	[2]	$ 312
Cost	[2]	312
Fair Value	[2]	$ 313
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Providers & Services | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			550%
Floor	[2]			3.45%
Interest Rate	[2],[5]			9.82%
Acquisition Date	[2]			Dec. 20, 2022
Maturity Date	[2]			Dec. 01, 2027
Par Amount	[2]			$ 312
Cost	[2]			309
Fair Value	[2]			$ 311
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11.62%
Acquisition Date	[2]	Feb. 10, 2023
Maturity Date	[2]	Jul. 08, 2025
Par Amount	[2]	$ 1,717
Cost	[2]	1,678
Fair Value	[2]	$ 1,717
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024
Schedule of Investments [Line Items]
Spread above Index	[4]			625%
Floor				1%
Interest Rate	[5]			10.92%
Acquisition Date				Nov. 29, 2022
Maturity Date				May 10, 2024
Par Amount				$ 567
Cost				557
Fair Value				$ 556
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Equipment & Supplies | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			650%
Floor	[2]			1%
Interest Rate	[2],[5]			10.91%
Acquisition Date	[2]			Aug. 17, 2022
Maturity Date	[2]			May 16, 2024
Par Amount	[2]			$ 1,087
Cost	[2]			1,080
Fair Value	[2]			$ 1,087
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+ 650 |1.00% | 11.96% | 8/17/2022 | 5/16/2024
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.96%
Acquisition Date	[2]	Aug. 17, 2022
Maturity Date	[2]	May 16, 2024
Par Amount	[2]	$ 1,677
Cost	[2]	1,671
Fair Value	[2]	$ 1,652
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Outset Medical Inc | Health Care Equipment & Supplies | S+515 | 2.75% | 10.48% | 11/3/2022 | 11/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2],[6]	515%
Floor	[2],[6]	2.75%
Interest Rate	[2],[3],[6]	10.48%
Acquisition Date	[2],[6]	Nov. 03, 2022
Maturity Date	[2],[6]	Nov. 01, 2027
Par Amount	[2],[6]	$ 3,052
Cost	[2],[6]	3,058
Fair Value	[2],[6]	$ 3,059
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4],[7]			515%
Floor	[2],[7]			2.75%
Interest Rate	[2],[5],[7]			9.33%
Acquisition Date	[2],[7]			Nov. 03, 2022
Maturity Date	[2],[7]			Nov. 01, 2027
Par Amount	[2],[7]			$ 3,052
Cost	[2],[7]			3,034
Fair Value	[2],[7]			$ 3,029
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+ 625 | 1.00% | 11.67% | 8/19/2022 | 12/4/2024
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11.67%
Acquisition Date	[2]	Aug. 19, 2022
Maturity Date	[2]	Dec. 04, 2024
Par Amount	[2]	$ 1,089
Cost	[2]	1,077
Fair Value	[2]	$ 1,089
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			625%
Floor	[2]			1%
Interest Rate	[2],[5]			10.67%
Acquisition Date	[2]			Aug. 19, 2022
Maturity Date	[2]			Dec. 04, 2024
Par Amount	[2]			$ 463
Cost	[2]			457
Fair Value	[2]			$ 459
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+ 500 | 1.00% | 10.44% | 8/26/2021 | 8/18/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	500%
Floor	[2]	1%
Interest Rate	[2],[3]	10.44%
Acquisition Date	[2]	Aug. 26, 2021
Maturity Date	[2]	Aug. 18, 2027
Par Amount	[2]	$ 3,871
Cost	[2]	3,832
Fair Value	[2]	$ 3,871
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			500%
Floor	[2]			1%
Interest Rate	[2],[5]			9.89%
Acquisition Date	[2]			Aug. 26, 2021
Maturity Date	[2]			Aug. 18, 2027
Par Amount	[2]			$ 3,107
Cost	[2]			3,069
Fair Value	[2]			$ 3,107
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | RQM+ Corp | Life Sciences Tools & Services | S+ 575 |1.00% | 11.40% | 8/20/2021 | 8/12/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	575%
Floor	[2]	1%
Interest Rate	[2],[3]	11.40%
Acquisition Date	[2]	Aug. 20, 2021
Maturity Date	[2]	Aug. 12, 2026
Par Amount	[2]	$ 4,002
Cost	[2]	3,965
Fair Value	[2]	$ 4,002
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			575%
Floor	[2]			1%
Interest Rate	[2],[5]			10.59%
Acquisition Date	[2]			Aug. 20, 2021
Maturity Date	[2]			Aug. 12, 2026
Par Amount	[2]			$ 4,033
Cost	[2]			3,986
Fair Value	[2]			$ 4,033
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 11.17% | 10/6/2022 | 10/5/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	575%
Floor	[2]	1%
Interest Rate	[2],[3]	11.17%
Acquisition Date	[2]	Oct. 06, 2022
Maturity Date	[2]	Oct. 05, 2029
Par Amount	[2]	$ 3,341
Cost	[2]	3,242
Fair Value	[2]	$ 3,341
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			575%
Floor	[2]			1%
Interest Rate	[2],[5]			9.46%
Acquisition Date	[2]			Oct. 06, 2022
Maturity Date	[2]			Oct. 05, 2029
Par Amount	[2]			$ 2,905
Cost	[2]			2,813
Fair Value	[2]			$ 2,810
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.89%| 6/3/2022 | 1/27/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11.89%
Acquisition Date	[2]	Jun. 03, 2022
Maturity Date	[2]	Jan. 27, 2026
Par Amount	[2]	$ 1,772
Cost	[2]	1,751
Fair Value	[2]	$ 1,737
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			600%
Floor	[2]			1%
Interest Rate	[2],[5]			10.77%
Acquisition Date	[2]			Jun. 03, 2022
Maturity Date	[2]			Jan. 27, 2026
Par Amount	[2]			$ 489
Cost	[2]			485
Fair Value	[2]			$ 489
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			570%
Floor	[2]			2.30%
Interest Rate	[2],[5]			9.88%
Acquisition Date	[2]			Sep. 21, 2022
Maturity Date	[2]			Sep. 01, 2027
Par Amount	[2]			$ 915
Cost	[2]			905
Fair Value	[2]			$ 906
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028
Schedule of Investments [Line Items]
Spread above Index	[2],[4]			575%
Floor	[2]			0.75%
Interest Rate	[2],[5]			10.48%
Acquisition Date	[2]			Jun. 16, 2021
Maturity Date	[2]			Jun. 16, 2028
Par Amount	[2]			$ 2,033
Cost	[2]			2,004
Fair Value	[2]			$ 2,033
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | S+ 550 | 0.75% | 10.99% | 6/16/2021 | 6/16/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	0.75%
Interest Rate	[2],[3]	10.99%
Acquisition Date	[2]	Jun. 16, 2021
Maturity Date	[2]	Jun. 16, 2028
Par Amount	[2]	$ 1,955
Cost	[2]	1,930
Fair Value	[2]	$ 1,955
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025
Schedule of Investments [Line Items]
Spread above Index	[1]	625%
Floor		1%
Interest Rate	[3]	11.79%
Acquisition Date		Sep. 18, 2023
Maturity Date		Sep. 15, 2025
Par Amount		$ 1,173
Cost		1,144
Fair Value		$ 1,143
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	675%
Floor	[2]	1%
Interest Rate	[2],[3]	12.29%
Acquisition Date	[2]	Mar. 30, 2023
Maturity Date	[2]	Mar. 30, 2029
Par Amount	[2]	$ 984
Cost	[2]	956
Fair Value	[2]	$ 984
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 2/7/2023 | 6/15/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11.79%
Acquisition Date	[2]	Feb. 07, 2023
Maturity Date	[2]	Jun. 15, 2026
Par Amount	[2]	$ 713
Cost	[2]	695
Fair Value	[2]	$ 706
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vapotherm Inc | Health Care Equipment & Supplies | S+ 930 |1.00% | 14.73% | 2/18/2022 | 2/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	930%
Floor	[2]	1%
Interest Rate	[2],[3],[9]	14.73%
Acquisition Date	[2]	Feb. 18, 2022
Maturity Date	[2]	Feb. 01, 2027
Par Amount	[2]	$ 3,308
Cost	[2]	3,342
Fair Value	[2]	$ 3,358
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4]			830%
Floor				1%
Interest Rate	[5],[10]			12.58%
Acquisition Date				Feb. 18, 2022
Maturity Date				Feb. 01, 2027
Par Amount				$ 3,095
Cost				3,094
Fair Value				$ 3,111
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	515%
Floor	[2]	4.75%
Interest Rate	[2],[3]	10.48%
Acquisition Date	[2]	Jun. 14, 2023
Maturity Date	[2]	Jul. 01, 2028
Par Amount	[2]	$ 567
Cost	[2]	561
Fair Value	[2]	$ 560
Investment, Identifier [Axis]: Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023
Schedule of Investments [Line Items]
Acquisition Date				Dec. 30, 2022
Maturity Date				Feb. 23, 2023
Par Amount				$ 30,000
Cost				29,828
Fair Value				29,828
Investment, Identifier [Axis]: Cash Equivalents | US Treasury Bill | Government | 9/30/2023 | 11/21/2023
Schedule of Investments [Line Items]
Acquisition Date		Sep. 30, 2023
Maturity Date		Nov. 21, 2023
Par Amount		$ 12,000
Cost		11,913
Fair Value		11,913
Investment, Identifier [Axis]: Common Equity/Warrants
Schedule of Investments [Line Items]
Cost		37
Fair Value		$ 12
Investment, Identifier [Axis]: Common Equity/Warrants | Assertio Holdings Inc Common Stock | Pharmaceuticals | 7/31/2023
Schedule of Investments [Line Items]
Acquisition Date	[11],[12]	Jul. 31, 2023
Par Amount	[11],[12]	$ 1,088
Cost	[11],[12]	4
Fair Value	[11],[12]	$ 3
Investment, Identifier [Axis]: Common Equity/Warrants | Meditrina Inc Warrants | Health Care Equipment & Supplies | 12/20/2022
Schedule of Investments [Line Items]
Acquisition Date	[12]	Dec. 20, 2022
Par Amount	[12]	$ 2,719
Cost	[12]	2
Fair Value	[12]	$ 2
Investment, Identifier [Axis]: Common Equity/Warrants | Vapotherm Inc Warrants | Health Care Equipment & Supplies | 2/18/2022
Schedule of Investments [Line Items]
Acquisition Date	[12]	Feb. 18, 2022
Par Amount	[12]	$ 4,395
Cost	[12]	27
Fair Value	[12]	$ 2
Investment, Identifier [Axis]: Common Equity/Warrants | Vertos Medical Inc Warrants | Health Care Equipment & Supplies | 6/14/2023
Schedule of Investments [Line Items]
Acquisition Date	[12]	Jun. 14, 2023
Par Amount	[12]	$ 13,779
Cost	[12]	4
Fair Value	[12]	5
Investment, Identifier [Axis]: Total Investments
Schedule of Investments [Line Items]
Cost		53,845	[13]	43,602	[14]
Fair Value		$ 54,328	[13]	43,897	[14]
Investment, Identifier [Axis]: Total Warrant
Schedule of Investments [Line Items]
Cost				25
Fair Value				$ 11
Investment, Identifier [Axis]: Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022
Schedule of Investments [Line Items]
Acquisition Date	[12]			Dec. 20, 2022
Par Amount	[12]			$ 2,719
Cost	[12]			2
Fair Value	[12]			$ 2
Investment, Identifier [Axis]: Warrants | Spectrum Pharmaceuticals Inc. | Biotechnology | 9/21/2022
Schedule of Investments [Line Items]
Acquisition Date	[12]			Sep. 21, 2022
Par Amount	[12]			$ 13,871
Cost	[12]			4
Fair Value	[12]			$ 1
Investment, Identifier [Axis]: Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022
Schedule of Investments [Line Items]
Acquisition Date	[12]			Feb. 18, 2022
Par Amount	[12]			$ 3,324
Cost	[12]			19
Fair Value	[12]			$ 8
[1]Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.[2]Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.[3]Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment the Company has provided the current interest rate in effect as of September 30, 2023.[4]Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.[5]Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2022.[6]Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of September 30, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 20.5% of the total assets of the Company.[7]Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis, non-qualifying assets in the portfolio represented 17.9% of the total assets of the Company.[8]BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.[9]Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.[10]Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.[11]Denotes a Level 1 investment.[12]Non-income producing security.[13]Aggregate net unrealized appreciation for U.S. federal income tax purposes is $117; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $545 and $428, respectively, based on a tax cost of $54,211. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.[14]Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Parenthetical) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023		Dec. 31, 2022
Schedule of Investments [Line Items]
Percentage of Non Qualifying Assets in the Portfolio of Total Assets	20.50%		17.90%
Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net	$ 117		$ 71
Tax Basis of Investments, Gross, Unrealized Appreciation	545		318
Tax Basis of Investments, Gross, Unrealized Depreciation	428		389
Tax Basis of Investments, Cost for Income Tax Purposes	$ 54,211		$ 43,968
Percentage Representing Bank Debt Or Senior Secured Loans Owned	235.50%		226.80%
Percentage Representing Shares/Warrants Owned	0.10%
Percentage Representing Warrants Owned			0.10%
Percentage Representing Total Investments In Investments Owned	235.60%	[1]	226.90%	[2]
Percentage Representing Cash Equivalents In Investments Owned	51.60%		154.10%
Percentage Representing Total Investments And Cash Equivalents In Investments Owned	287.20%		381%
Percentage Representing Liabilities In Excess Of Other Assets In Investments Owned	187.20%		281%
Percentage Representing Net Assets In Investments Owned	100%		100%
BridgeBio Pharma Inc [Member]
Schedule of Investments [Line Items]
Rate of coupon as PIK	3%		3%
Vapotherm, Inc. [Member]
Schedule of Investments [Line Items]
Rate of coupon as PIK	9%		8%
[1]Aggregate net unrealized appreciation for U.S. federal income tax purposes is $117; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $545 and $428, respectively, based on a tax cost of $54,211. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.[2]Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 410	$ 165	$ 1,139	$ 608

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization

Organization	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1. Organization SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as a closed-end, In connection with the Company’s formation, the Company issued and sold 40 units to the Adviser (the “Initial Unitholder”), which were acquired for an initial capital contribution of $1 on January 5, 2021 in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. The Company’s capital commitments total $83,850. The Company’s initial drawdown occurred on March 8, 2021 with the sale and issuance of units at an aggregate purchase price of $3,500 or $29.30 per unit. Prior to the issuance of units on March 8, 2021, the Initial Unitholder’s initial seed capital was withdrawn from the Company and its Units were canceled. As of September 30, 2023, $24,000 of capital commitments were drawn and $59,850 were unfunded. The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25,000 and $100,000. These aggregate loan tranches are expected to range in size from $100,000 to $300,000. Healthcare cash flow loans are generally expected to have a five pre-commercialization four two non-investment The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). The Company was permitted to hold closings at any time during the offering period (the “Offering Period”), which ended on December 31, 2022. The term of the Company is expected to be seven years from the Company’s final closing with the Access Fund, which was held on February 11, 2021, unless the Company is terminated earlier or causes the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”) as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a non-1940 At any time prior to the end of the term, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange. In connection with any such Exchange Listing, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the board of directors, either through a conversion in accordance with applicable law, a merger with or into an existing corporation, or otherwise, in which all units will be converted into or exchanged for shares of common stock of the resulting corporation. If the Company is unable to effectuate an Exchange Listing prior to the end of the term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q S-X, In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of financial statements, have been included. The significant accounting policies consistently followed by the Company are: (a) Investment transactions are accounted for on the trade date; (b) In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows: (i) securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation; (ii) exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes; (iii) short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and (iv) securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below: a. the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment; b. preliminary valuation conclusions are then documented and discussed with senior management of the Adviser; c. the audit committee of the Board of Directors (the “Board”) reviews the preliminary valuations of the Adviser and third-party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and d. the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third-party valuation specialist, if any, which may from time to time be engaged by the Board. The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion. The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 2a-5. When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC 820-10, ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy: Level 1 Level 2 Level 3 In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience. (c) Gains or losses on investments are calculated by using the specific identification method. (d) The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other non-recurring (e) The Company intends to comply with the applicable provisions of the Code pertaining to RICs to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate. (f) Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP. (g) Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually. (h) In accordance with Regulation S-X Consolidation (i) The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company. (j) In accordance with ASC 835-30, (k) The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC 946-20-25. (l) Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual non-accrual (m) The Company records expenses directly related to its organization as incurred. (n) The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.

Agreements and Related Party Tr

Agreements and Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Agreements And Related Party Transactions [Abstract]
Agreements and Related Party Transactions	Note 3. Agreements and Related Party Transactions Pursuant to the Investment Management Agreement we have entered into with the Adviser, we intend to pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, the Adviser has been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay an administration fee to the Administrative Coordinator for such administrative and coordination services, each as defined and described further below. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders. Management Fees The Company will pay the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Pre-Exchange Pre-Exchange • Pre-Exchange Pre-Exchange per annum • Post-Exchange Listing The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the management fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent. The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee. No Management Fees have been waived as of September 30, 2023. Incentive Fee Distributions Pre-Exchange “Pre-Exchange (i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a Pre-Exchange (A) First, Return of Capital Contributions: 100% to such Unitholder until such Unitholders has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay Pre-Exchange Pre-Exchange (B) Second, Unitholder Preferred Return: 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clause (ii)(A) and (ii)(C) below equal to 6% per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay Pre-Exchange Pre-Exchange “—Pre-Exchange (C) Third, Adviser Catch Up: 100% of all remaining Disposition Proceeds to the Adviser as a Pre-Exchange (D) Fourth, 90%/10%: 90% of all remaining Disposition Proceeds to Unitholders and 10% of all remaining Disposition Proceeds to the Adviser as a Pre-Exchange In no event will the Adviser receive amounts of Pre-Exchange In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation. (ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a Pre-Exchange (A) First, Unitholder Preferred Return: 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return; (B) Second, Adviser Catch Up: Second, 100% of all remaining Current Proceeds to the Adviser as a Pre-Exchange (C) Third, 90%/10%: Thereafter, 90% of all remaining Current Proceeds to Unitholders and 10% of all remaining Current Proceeds to the Adviser as a Pre-Exchange In no event will the Adviser receive amounts of Pre-Exchange Post-Exchange Listing Incentive Fee (i) Pre-Incentive a. For this purpose, Pre-Incentive b. Pre-Incentive Pre-Incentive Pre-Incentive c. The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s Pre-Incentive i. no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s Pre-Incentive ii. 100% of the Company’s Pre-Incentive Pre-Incentive Pre-Incentive “catch-up.” “catch-up” Pre-Incentive Pre-Incentive iii. 20% of the amount of the Company’s Pre-Incentive catch-up Pre-Incentive These calculations will be appropriately pro-rated for Capital Gains Fee Administration Fees and Expenses Pre-Exchange “Pre-Exchange Pre-Exchange on-going, non-investment-related The Pre-Exchange The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the Pre-Exchange Pre-Exchange Pre-Exchange Post-Exchange Listing Administration Expenses Pre-Exchange For the three and nine months ended September 30, 2023, the Company incurred $143 and $408, respectively, in Management Fees, $10 and $30, respectively, in administration fees and $0 and $0, respectively, in incentive fees. For the three and nine months ended September 30, 2022, the Company incurred $118 and $291, respectively, in Management Fees, $7 and $19, respectively, in administration fees and $0 and $0, respectively, in incentive fees. In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400,000 in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in Commitments, $2,250 (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s Portfolio Investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing. The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $177 of offering expenses were charged to capital and $229 of organizational costs were expensed.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 4. Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows: Level 1. Level 2. a) Quoted prices for similar assets or liabilities in active markets; b) Quoted prices for identical or similar assets or liabilities in non-active c) Pricing models whose inputs are observable for substantially the full term of the asset or liability; and d) Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability. Level 3. When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3). A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1. The following tables present the balances of assets measured at fair value on a recurring basis, as of September 30, 2023 and December 31, 2022: Fair Value Measurements As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ —   $ —  $ 54,316 $ 54,316 Common Equity/Warrants 3 —  9 12 Total Investments $ 3 $ —  $ 54,325 $ 54,328 While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at September 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $19,610 and $13,800, respectively. Fair Value Measurements As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ —  $ —  $ 43,886 $ 43,886 Warrants —  —  11 11 Total Investments $ —  $ —  $ 43,897 $ 43,897 While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $14,675 and $13,800, respectively. The following table provides a summary of the changes in fair value of Level 3 assets for the three and nine months ended September 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at September 30, 2023: Bank Debt/Senior Warrants Total Fair value, June 30, 2023 $ 52,351 $ 15 $ 52,366 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 135 (4 ) 131 Purchase of investment securities* 3,251 2 3,253 Proceeds from dispositions of investment securities (1,421 ) (4 ) (1,425 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, September 30, 2023 $ 54,316 $ 9 $ 54,325 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 150 $ (1 ) $ 149 Bank Debt/Senior Warrants Total Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 199 (10 ) 189 Purchase of investment securities* 15,750 12 15,762 Proceeds from dispositions of investment securities (5,519 ) (4 ) (5,523 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, September 30, 2023 $ 54,316 $ 9 $ 54,325 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 200 $ (13 ) $ 187 * Includes PIK capitalization and accretion of discount The following tables provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022: Bank Debt/Senior Warrants Total Fair value, December 31, 2021 $ 27,286 $ —  $ 27,286 Total gains or losses included in earnings: Net realized gain —  —  —  Net change in unrealized gain (loss) 192 (14 ) 178 Purchase of investment securities 28,713 25 28,738 Proceeds from dispositions of investment securities (12,305 ) —  (12,305 ) Transfers into Level 3 —  —  —  Transfers out of Level 3 —  —  —  Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 243 $ (14 ) $ 229 Quantitative Information about Level 3 Fair Value Measurements The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company. Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities. Quantitative information about the Company’s Level 3 asset fair value measurements as of September 30, 2023 is summarized in the table below: Asset or Liability Fair Value at September 30, Principal Valuation Technique/Methodology Unobservable Input Range (Weighted Average) Bank Debt / Senior Secured Loans Asset $ 54,316 Income Approach Market Yield 10.7% – 18.2% Warrants Asset $ 9 Market Approach Volatility 17.8% -17.8% (17.8%) Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving bid-ask Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: Asset or Liability Fair Value at December 31, Principal Valuation Technique/Methodology Unobservable Input Range (Weighted Average) Bank Debt / Senior Secured Loans Asset $ 43,886 Income Approach Market Yield 9.8% – 18.2% (12.5% ) Warrants Asset $ 11 Market Approach Volatility 26.0% - 26.0% (26.0% ) Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving bid-ask Generally

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Note 5. Debt SPV Facility Subscription Facility 2.75-3.00% The average annualized interest cost for borrowings for the nine months ended September 30, 2023 and the year ended December 31, 2022 was 7.95% and 4.88%, respectively. These costs are exclusive of other credit facility expenses such as unused fees. The maximum amount borrowed on the credit facilities during the nine months ended September 30, 2023 and the year ended December 31, 2022 was $33,410 and $32,775, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of September 30, 2023 and December 31, 2022 is $14,970 and $15,513, respectively, comprised of the following: September 30, December 31, Outset Medical, Inc. $ 3,052 $ 3,052 Apeel Technology, Inc. 2,852 2,852 Southern Orthodontic Partners Management, LLC 1,654 670 CVAUSA Management, LLC 1,354 —  Orthopedic Care Partners Management, LLC 901 566 Cerapedics, Inc. 853 623 ONS MSO, LLC 814 —  Arcutis Biotherapeutics, Inc. 786 786 Ardelyx, Inc. 696 696 SCP Eye Care, LLC 510 968 United Digestive MSO Parent, LLC 391 —  Urology Management Holdings, Inc. 359 —  UVP Management, LLC 333 —  Vertos Medical, Inc. 283 —  SunMed Group Holdings, LLC 132 69 Glooko, Inc. —  1,633 Oral Surgery Partners Holdings, LLC —  843 Plastics Management, LLC —  794 Spectrum Pharmaceuticals, Inc. —  763 Pediatric Home Respiratory Services, LLC —  630 Meditrina, Inc. —  312 Ivy Fertility Services, LLC —  128 BayMark Health Services, Inc. —  128 Total Commitments $ 14,970 $ 15,513 The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of September 30, 2023, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment. In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with off-balance off-balance

Unitholders' Capital

Unitholders' Capital	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Unitholders' Capital	Note 7. Unitholders’ Capital Transactions in Unitholders’ capital were as follows: Three months Three months Units at beginning of period 1,069,642 682,427 Units issued —  —  Units issued and outstanding at end of period 1,069,642 682,427 Nine months Nine months Units at beginning of period 888,565 682,427 Units issued 181,077 —  Units issued and outstanding at end of period 1,069,642 682,427

Financial Highlights

Financial Highlights	9 Months Ended
	Sep. 30, 2023
Investment Company, Financial Highlights [Abstract]
Financial Highlights	Note 8. Financial Highlights The following is a schedule of financial highlights for the nine months ended September 30, 2023 and September 30, 2022: Nine months ended Nine months ended Per Share Data: (a) Net asset value per Unit, beginning of period $ 21.77 $ 21.41 Net investment income 0.95 0.63 Net realized and unrealized gain 0.24 * 0.26 Net increase in Unitholders’ capital resulting from operations 1.19 0.89 Distributions to Unitholders: From distributable earnings (1.40 ) (0.51 ) Net asset value per Unit, end of period $ 21.56 $ 21.79 Total Return (b)(c) 5.47 % 4.16 % Unitholders’ capital, end of period $ 23,065 $ 14,871 Units outstanding, end of period 1,069,642 682,427 Ratios to average net assets of Unitholders’ Capital (c): Net investment income 4.35 % 2.90 % Operating expenses 4.50 % 5.10 % Interest and other credit facility expenses 12.83 % 8.03 % Total expenses 17.33 % 13.13 % Average debt outstanding $ 30,079 $ 18,129 Portfolio turnover ratio 11.1 % 14.6 % (a) Calculated using the average Units outstanding method. Weighted average Units outstanding for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were 1,015,916 and 682,427, respectively. (b) Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per Unit. Total return does not include a sales load. (c) Not annualized for periods less than one year. * Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 9. Subsequent Events The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure in these consolidated financial statements.

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on a Recurring Basis	The following tables present the balances of assets measured at fair value on a recurring basis, as of September 30, 2023 and December 31, 2022: Fair Value Measurements As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ —   $ —  $ 54,316 $ 54,316 Common Equity/Warrants 3 —  9 12 Total Investments $ 3 $ —  $ 54,325 $ 54,328 Fair Value Measurements As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ —  $ —  $ 43,886 $ 43,886 Warrants —  —  11 11 Total Investments $ —  $ —  $ 43,897 $ 43,897
Summary of Changes in Fair Value of Level 3 Assets	The following table provides a summary of the changes in fair value of Level 3 assets for the three and nine months ended September 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at September 30, 2023: Bank Debt/Senior Warrants Total Fair value, June 30, 2023 $ 52,351 $ 15 $ 52,366 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 135 (4 ) 131 Purchase of investment securities* 3,251 2 3,253 Proceeds from dispositions of investment securities (1,421 ) (4 ) (1,425 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, September 30, 2023 $ 54,316 $ 9 $ 54,325 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 150 $ (1 ) $ 149 Bank Debt/Senior Warrants Total Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 199 (10 ) 189 Purchase of investment securities* 15,750 12 15,762 Proceeds from dispositions of investment securities (5,519 ) (4 ) (5,523 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, September 30, 2023 $ 54,316 $ 9 $ 54,325 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 200 $ (13 ) $ 187 * Includes PIK capitalization and accretion of discount The following tables provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022: Bank Debt/Senior Warrants Total Fair value, December 31, 2021 $ 27,286 $ —  $ 27,286 Total gains or losses included in earnings: Net realized gain —  —  —  Net change in unrealized gain (loss) 192 (14 ) 178 Purchase of investment securities 28,713 25 28,738 Proceeds from dispositions of investment securities (12,305 ) —  (12,305 ) Transfers into Level 3 —  —  —  Transfers out of Level 3 —  —  —  Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 243 $ (14 ) $ 229
Summary of Company's Level 3	Quantitative information about the Company’s Level 3 asset fair value measurements as of September 30, 2023 is summarized in the table below: Asset or Liability Fair Value at September 30, Principal Valuation Technique/Methodology Unobservable Input Range (Weighted Average) Bank Debt / Senior Secured Loans Asset $ 54,316 Income Approach Market Yield 10.7% – 18.2% Warrants Asset $ 9 Market Approach Volatility 17.8% -17.8% (17.8%) Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: Asset or Liability Fair Value at December 31, Principal Valuation Technique/Methodology Unobservable Input Range (Weighted Average) Bank Debt / Senior Secured Loans Asset $ 43,886 Income Approach Market Yield 9.8% – 18.2% (12.5% ) Warrants Asset $ 11 Market Approach Volatility 26.0% - 26.0% (26.0% )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Unfunded Commitments	September 30, December 31, Outset Medical, Inc. $ 3,052 $ 3,052 Apeel Technology, Inc. 2,852 2,852 Southern Orthodontic Partners Management, LLC 1,654 670 CVAUSA Management, LLC 1,354 —  Orthopedic Care Partners Management, LLC 901 566 Cerapedics, Inc. 853 623 ONS MSO, LLC 814 —  Arcutis Biotherapeutics, Inc. 786 786 Ardelyx, Inc. 696 696 SCP Eye Care, LLC 510 968 United Digestive MSO Parent, LLC 391 —  Urology Management Holdings, Inc. 359 —  UVP Management, LLC 333 —  Vertos Medical, Inc. 283 —  SunMed Group Holdings, LLC 132 69 Glooko, Inc. —  1,633 Oral Surgery Partners Holdings, LLC —  843 Plastics Management, LLC —  794 Spectrum Pharmaceuticals, Inc. —  763 Pediatric Home Respiratory Services, LLC —  630 Meditrina, Inc. —  312 Ivy Fertility Services, LLC —  128 BayMark Health Services, Inc. —  128 Total Commitments $ 14,970 $ 15,513

Unitholders' Capital (Tables)

Unitholders' Capital (Tables)	9 Months Ended
	Sep. 30, 2023
Limited Liability Company (LLC) Members' Equity [Abstract]
Summary of Limited Liability Company Unit Holders Capital	Transactions in Unitholders’ capital were as follows: Three months Three months Units at beginning of period 1,069,642 682,427 Units issued —  —  Units issued and outstanding at end of period 1,069,642 682,427 Nine months Nine months Units at beginning of period 888,565 682,427 Units issued 181,077 —  Units issued and outstanding at end of period 1,069,642 682,427

Financial Highlights (Tables)

Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2023
Investment Company, Financial Highlights [Abstract]
Summary of Financial Highlights	The following is a schedule of financial highlights for the nine months ended September 30, 2023 and September 30, 2022: Nine months ended Nine months ended Per Share Data: (a) Net asset value per Unit, beginning of period $ 21.77 $ 21.41 Net investment income 0.95 0.63 Net realized and unrealized gain 0.24 * 0.26 Net increase in Unitholders’ capital resulting from operations 1.19 0.89 Distributions to Unitholders: From distributable earnings (1.40 ) (0.51 ) Net asset value per Unit, end of period $ 21.56 $ 21.79 Total Return (b)(c) 5.47 % 4.16 % Unitholders’ capital, end of period $ 23,065 $ 14,871 Units outstanding, end of period 1,069,642 682,427 Ratios to average net assets of Unitholders’ Capital (c): Net investment income 4.35 % 2.90 % Operating expenses 4.50 % 5.10 % Interest and other credit facility expenses 12.83 % 8.03 % Total expenses 17.33 % 13.13 % Average debt outstanding $ 30,079 $ 18,129 Portfolio turnover ratio 11.1 % 14.6 % (a) Calculated using the average Units outstanding method. Weighted average Units outstanding for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were 1,015,916 and 682,427, respectively. (b) Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per Unit. Total return does not include a sales load. (c) Not annualized for periods less than one year. * Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.

Organization - Additional Infor

Organization - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended
	Mar. 08, 2021	Jan. 05, 2021	Sep. 30, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Unfunded commitments			$ 14,970	$ 15,513
Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Capital commitments			2,250
Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Capital commitments			1,250
Initial Unitholder [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common shares shares		40
Share price	$ 29.3	$ 1
Capital commitments			83,850
Issuance of common shares value	$ 3,500
Withdrawal of capital commitments			24,000
Unfunded commitments			$ 59,850
First Lien Health Care Cash Flow Loans [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument maturity date			five to six year
Debt Instrument, Frequency of Periodic Payment			three years
Debt Instrument, Payment Terms			often repaid within three years
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 300,000
Debt Instrument, Term			6 years
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member] | EBITDA Concentration Risk [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Earnings Before Interest Tax Depreciation And Amortization			$ 100,000
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 100,000
Debt Instrument, Term			5 years
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member] | EBITDA Concentration Risk [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Earnings Before Interest Tax Depreciation And Amortization			$ 25,000
First Lien Life Science Loans [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument maturity date			four to five year
Debt Instrument, Payment Terms			often repaid within two to three years
First Lien Life Science Loans [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 150,000
Debt Instrument, Term			5 years
Debt Instrument, Frequency of Periodic Payment			three years
First Lien Life Science Loans [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 25,000
Debt Instrument, Term			4 years
Debt Instrument, Frequency of Periodic Payment			two years

Summary of Significant Accoun_2

Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2023
Schedule Of Significant Accounting Policies [Line Items]
Excise tax rate	4%

Agreements and Related Party _2

Agreements and Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Agreements And Related Party Transactions [Line Items]
Percentage of pre exchange management fee on invested capital				1.50%
Percentage of Post-Exchange Listing Management Fee on Entity Average Assets				1.50%
Percentage of Entity Average Assets Threshold				1%
Precentage of product payment				200%
Percentage of cummulative capital realized gains				20%
Percentage of Post-Exchange Listing Management Fee on Entity Gross Assets				1.50%
Percentage pre incentive fee net investment income				100%
Percentage of realized capital gains				20%
Percentage of average cost basis				0.08%
Management fee expense		$ 143	$ 118	$ 408	$ 291
Administrative fees expense		10	7	30	19
Incentive fee expense		0	$ 0	$ 0	$ 0
Product of capital commitment				0.0025
Affiliate Costs				$ 500
Offering expenses	$ 177
Organizational costs	$ 229
Type of agreement, First [Member]
Agreements And Related Party Transactions [Line Items]
Precentage of return of capital contributions				100%
Percentage of current proceeds to unitholders				100%
Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				100%
Percentage of current proceeds to advisers				100%
Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to adviser				100%
Quarterly [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of hurdle rate				1.50%
Percentage pre incentive fee net investment income				1.875%
Annually [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of hurdle rate				6%
Percentage pre incentive fee net investment income				7.50%
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of current proceeds to unitholders				90%
Percentage of current proceeds to advisers				10%
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				90%
Percentage of remaining disposition proceeds to adviser				10%
Adviser [Member]
Agreements And Related Party Transactions [Line Items]
Percentage pre incentive fee net investment income				20%
Minimum [Member]
Agreements And Related Party Transactions [Line Items]
Commitments		400,000		$ 400,000
Capital commitments		1,250		$ 1,250
Minimum [Member] | Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				6%
Minimum [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Pecentage of amount due to unitholders				10%
Percentage of current proceeds to unitholders				10%
Minimum [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				10%
Maximum [Member]
Agreements And Related Party Transactions [Line Items]
Commitments		400,000		$ 400,000
Capital commitments		$ 2,250		$ 2,250
Maximum [Member] | Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Pecentage of amount due to unitholders				10%
Maximum [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of current proceeds to unitholders				90%
Maximum [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				90%

Fair Value - Summary of Assets

Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	$ 54,328	$ 43,897
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	3	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	54,325	43,897
Bank Debt Senior Secured Loans [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	54,316	43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	54,316	43,886
Common Equity/Warrants [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	12
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	3
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	$ 9
Warrant [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure		11
Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure		0
Warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure		0
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure		$ 11

Fair Value - Summary of Changes

Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) - Investments [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023		Sep. 30, 2023		Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 52,366		$ 43,897		$ 27,286
Total gains or losses included in earnings:
Purchase of investment securities	3,253	[1]	15,762	[1]	28,738
Proceeds from dispositions of investment securities	(1,425)		(5,523)		(12,305)
Transfers into Level 3	0		0		0
Transfers out of Level 3	0		0		0
Closing balance	54,325		54,325		43,897
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)	149		187		229
Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	0		0		0
Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	131		189		178
Bank Debt Senior Secured Loans [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	52,351		43,886		27,286
Total gains or losses included in earnings:
Purchase of investment securities	3,251	[1]	15,750	[1]	28,713
Proceeds from dispositions of investment securities	(1,421)		(5,519)		(12,305)
Transfers into Level 3	0		0		0
Transfers out of Level 3	0		0		0
Closing balance	54,316		54,316		43,886
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)	150		200		243
Bank Debt Senior Secured Loans [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	0		0		0
Bank Debt Senior Secured Loans [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	135		199		192
Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	15		11		0
Total gains or losses included in earnings:
Purchase of investment securities	2	[1]	12	[1]	25
Proceeds from dispositions of investment securities	(4)		(4)		0
Transfers into Level 3	0		0		0
Transfers out of Level 3	0		0		0
Closing balance	9		9		11
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)	(1)		(13)		(14)
Warrant [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	0		0		0
Warrant [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Unrealized gain (loss)	$ (4)		$ (10)		$ (14)
[1]Includes PIK capitalization and accretion of discount

Fair Value - Summary of Company

Fair Value - Summary of Company's Level 3 (Detail) - Fair Value, Recurring [Member] $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 54,328	$ 43,897
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	54,325	43,897
Bank Debt Senior Secured Loans [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	54,316	43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 54,316	$ 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset	Asset
Investments, Fair Value Disclosure	$ 54,316	$ 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	10.7	9.8
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	18.2	18.2
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	13.1	12.5
Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure		$ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure		$ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset	Asset
Investments, Fair Value Disclosure	$ 9	$ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	17.8	26
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	17.8	26
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	17.8	26

Fair Value - Additional Informa

Fair Value - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
SPV Facility [Member]
Fair Value [Line Items]
Debt instrument carrying amount	$ 19,610	$ 14,675
Subscription Facility [Member]
Fair Value [Line Items]
Debt instrument carrying amount	$ 13,800	$ 13,800

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Feb. 18, 2022	Mar. 19, 2021
Line of Credit Facility [Line Items]
Long-Term Debt, Weighted Average Interest Rate, over Time	7.95%	4.88%
Line of Credit Facility, Maximum Amount Outstanding During Period	$ 33,410	$ 32,775
SPV Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt, Gross	19,610	14,675
Subscription Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt, Gross	$ 13,800	$ 13,800
JPMorgan Chase Bank, N.A. [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Expiration Date	Feb. 18, 2027
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.875%
Line of Credit Facility, Collateral	The SPV Facility is secured by all of the assets held by the SPV
Long-Term Debt, Gross	$ 19,610
JPMorgan Chase Bank, N.A. [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.07%
Debt Instrument, Description of Variable Rate Basis	Term SOFR
Debt Instrument, Description Of Floor Requirement	no SOFR
JPMorgan Chase Bank, N.A. [Member] | Maximum [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 75,000
JPMorgan Chase Bank, N.A. [Member] | Minimum [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 50,000
ING Capital LLC [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 25,000
Line of Credit Facility, Expiration Date	Mar. 15, 2024
ING Capital LLC [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Description of Variable Rate Basis	SOFR
ING Capital LLC [Member] | Maximum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3%
ING Capital LLC [Member] | Minimum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.75%

Commitments and Contingencies -

Commitments and Contingencies - Summary of Unfunded Commitments (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	$ 14,970	$ 15,513
Outset Medical, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	3,052	3,052
Apeel Technology, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	2,852	2,852
Southern Orthodontic Partners Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	1,654	670
CVAUSA Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	1,354	0
Orthopedic Care Partners Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	901	566
Cerapedics, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	853	623
ONS MSO, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	814	0
Arcutis Biotherapeutics, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	786	786
Ardelyx, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	696	696
SCP Eye Care, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	510	968
United Digestive MSO Parent, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	391	0
Urology Management Holdings, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	359	0
UVP Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	333	0
Vertos Medical, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	283	0
SunMed Group Holdings, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	132	69
Glooko, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	1,633
Oral Surgery Partners Holdings, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	843
Plastics Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	794
Spectrum Pharmaceuticals, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	763
Pediatric Home Respiratory Services, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	630
Meditrina, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	312
Ivy Fertility Services, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	128
BayMark Health Services, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	$ 0	$ 128

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Unfunded Commitments	$ 14,970	$ 15,513

Unitholders' Capital - Summary

Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) - shares		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Units at beginning of period		1,069,642	682,427	888,565	682,427
Units issued		0	0	181,077	0
Units issued at end of period		1,069,642	682,427	1,069,642	682,427
Units outstanding at end of period	[1],[2]	1,069,642	682,427	1,069,642	682,427
[1]Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per Unit. Total return does not include a sales load.[2]Not annualized for periods less than one year.

Financial Highlights - Summary

Financial Highlights - Summary of Financial Highlights (Detail) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022		Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Investment Company, Financial Highlights [Line Items]
Net asset value per Unit, beginning of period	[1]	$ 21.77		$ 21.41
Net investment income	[1]	0.95		0.63
Net realized and unrealized gain	[1]	0.24	[2]	0.26
Net increase in Unitholders' capital resulting from operations	[1]	1.19		0.89
From distributable earnings		(1.4)		(0.51)
Net asset value per Unit, end of period		$ 21.56		$ 21.79
Total Return	[3],[4]	5.47%		4.16%
Unitholders' capital, end of period		$ 23,065	[3],[4]	$ 14,871	[3],[4]		$ 19,348
Units outstanding, end of period		1,069,642	[3],[4]	682,427	[3],[4]	1,069,642	888,565	682,427	682,427
Ratios to average net assets of Unitholders' Capital :
Net investment income	[4]	4.35%		2.90%
Operating expenses	[4]	4.50%		5.10%
Interest and other credit facility expenses	[4]	12.83%		8.03%
Total expenses	[4]	17.33%		13.13%
Average debt outstanding	[4]	$ 30,079		$ 18,129
Portfolio turnover ratio	[4]	11.10%		14.60%
[1]Calculated using the average Units outstanding method. Weighted average Units outstanding for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were 1,015,916 and 682,427, respectively.[2]Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.[3]Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per Unit. Total return does not include a sales load.[4]Not annualized for periods less than one year.

Financial Highlights - Summar_2

Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Investment Company, Financial Highlights [Abstract]
Weighted average number of units outstanding	1,015,916	682,427